Allezoe Medical Holdings, Inc. announced today that its SureScreen Medical, Inc. subsidiary has received notice from the European Patent Office that it intends to grant the requested patent for the “see and treat” HPV virus diagnosis and treatment technology SureScreen is developing under an exclusive license, as soon as the remaining procedural steps have been completed. As a result, SureScreen has filed German and French claims translations at the European Patent Office together with the necessary request for further processing of the patent application for the technology. With completion of these actions, all of the procedural steps for the grant of the patent now have been undertaken, and the application has been placed in the queue for publication as a granted patent. The US patent application remains under review by the US Patent & Trademark Office.
SureScreen is developing the “see and treat” technology under a licensing agreement that grants it exclusive worldwide rights to develop, seek patent protection for, and market the technology. The “see and treat” technology aims to allow healthcare professionals to detect and treat the most common sexually transmitted infection, and a cause of cervical cancer, Human Papillomavirus (HPV), in a single visit. According to Caroline Pinnell, President and COO of ALZM and Chairman of the SureScreen subsidiary: “We are pleased and excited about the continued development of SureScreen’s “see and treat” technology and its potential impact on the health of women worldwide. Its development, along with the recently-announced acquisition of OVWatch, is another boost to the growing line up of Allezoe Medical subsidiaries’ cutting edge technologies.”
Let us hear your thoughts below: